Podcasts
Listen to the latest hemonc news from international experts
The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML
The acute myeloid leukemia (AML) field has witnessed rapid evolution of late, with exciting developments in strategies for the treatment of the disease.
In this podcast, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, chairs a discussion with Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, and Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia. The spreakers debate the key updates in the treatment of AML from the recent ASCO and EHA 2020 virtual meetings including emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML.
Date: 16th July 2020
